IOVANCE BIOTHERAPEUTICS Files 8-K: Board & Executive Changes
Ticker: IOVA · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000041666 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes, filing
Related Tickers: IOVA
TL;DR
IOVA board shakeup and exec comp changes filed. Keep an eye on strategy shifts.
AI Summary
On March 26, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the appointment of new officers and potential amendments to the company's articles of incorporation or bylaws. It also covers financial statements and exhibits, indicating ongoing operational and financial disclosures.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and governance can introduce uncertainty, but the filing also includes standard financial disclosures.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- March 26, 2024 (date) — Date of earliest event reported
- 0001104659-24-041200 (filing_id) — Accession Number
FAQ
What specific changes were made to the board of directors?
The filing indicates a 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
Were there any changes in executive officers?
Yes, the filing lists 'Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting changes or updates regarding executive positions and their compensation.
Does this filing include any financial statements?
Yes, the filing explicitly states 'ITEM INFORMATION: Financial Statements and Exhibits' as part of the report.
Are there any amendments to the company's governing documents mentioned?
Yes, the filing includes 'ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year', indicating potential changes to the company's foundational legal documents.
What is the Central Index Key (CIK) for IOVANCE BIOTHERAPEUTICS, INC.?
The Central Index Key for IOVANCE BIOTHERAPEUTICS, INC. is 0001425205.
Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 9.5 · Accepted 2024-03-29 17:00:36
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Marke
Filing Documents
- tm2410183d1_8k.htm (8-K) — 28KB
- tm2410183d1_ex3-1.htm (EX-3.1) — 295KB
- 0001104659-24-041200.txt ( ) — 547KB
- iova-20240326.xsd (EX-101.SCH) — 3KB
- iova-20240326_lab.xml (EX-101.LAB) — 33KB
- iova-20240326_pre.xml (EX-101.PRE) — 22KB
- tm2410183d1_8k_htm.xml (XML) — 4KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 26, 2024, General (Ret.) Merrill A. McPeak, a member of the Board of Directors (the " Board ") of Iovance Biotherapeutics, Inc. (the " Company "), provided notice to the Board that he will retire and not be standing for re-election to the Board at the Company's annual meeting of stockholders (the " Annual Meeting ") currently anticipated to be held in June 2024. General McPeak will serve out his current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and General McPeak on any matter regarding the Company's operations, policies, or practices. The Company thanks General McPeak for his service to the Board. On March 26, 2024, the Nominating and Corporate Governance Committee of the Board recommended that Frederick G. Vogt, Ph.D., J.D., the Company's Interim Chief Executive Officer and President, and General Counsel, be nominated to stand for election to the Board at the Annual Meeting, to fill the vacancy created by General McPeak's retirement. If elected, Dr. Vogt's term as a director of the Company will be effective as of the date of the Annual Meeting.
03 Amendments to the Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to the Articles of Incorporation or Bylaws; Change in Fiscal Year. On March 28, 2024, the Board unanimously adopted the Company's Fourth Amended and Restated Bylaws (as amended and restated, the " Bylaws "), effective immediately, to modify the definition of "Acting in Concert" contained therein. The foregoing description of the amendments made to the Bylaws is qualified by reference to the Bylaws, a copy of which is attached hereto as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits Exhibit No. Description 3.1 Fourth Amended and Restated Bylaws of Iovance Biotherapeutics, Inc. 104 Cover Page Interactive Data File (embedded as Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 29, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Interim CEO & General Counsel